CHU Ambroise Paré

Mons 7000

0 studies enrolling now · 11 studies all time

What they study most

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Breast Cancer, Carcinoma, Non-Squamous Non-Small Cell Lung, First Line Non-Small Cell Lung Cancer, Lung Adenocarcinoma Stage IIIB/IV, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Small-cell Lung Cancer, Triple Negative Breast Cancer

Studies at this site

• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer — Stopped early
• Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) — Completed
• A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer — Completed
• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer — Completed
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) — Completed
• Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer — Completed
• A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) — Completed
• Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer — Completed
• A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer — Completed